Biogen Inc. $BIIB Stake Raised by AIA Group Ltd

AIA Group Ltd grew its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 223.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,161 shares of the biotechnology company’s stock after purchasing an additional 15,309 shares during the period. AIA Group Ltd’s holdings in Biogen were worth $3,104,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in BIIB. Elevation Point Wealth Partners LLC bought a new position in shares of Biogen in the second quarter valued at $25,000. Rothschild Investment LLC grew its holdings in shares of Biogen by 64.7% in the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 88 shares during the last quarter. Accredited Wealth Management LLC raised its position in shares of Biogen by 1,233.3% during the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 185 shares during the period. WFA of San Diego LLC acquired a new stake in shares of Biogen during the second quarter worth $32,000. Finally, True Wealth Design LLC lifted its holdings in shares of Biogen by 62.9% during the third quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 90 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. HSBC increased their price target on Biogen from $143.00 to $150.00 and gave the company a “reduce” rating in a research report on Tuesday. Canaccord Genuity Group boosted their price objective on Biogen from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Monday, February 9th. The Goldman Sachs Group reiterated a “buy” rating on shares of Biogen in a report on Monday, February 9th. Morgan Stanley set a $190.00 target price on shares of Biogen in a research report on Sunday, February 8th. Finally, Mizuho boosted their price target on shares of Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. Twelve investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $205.31.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Late‑breaking Phase 2 AMETHYST Part A data for litifilimab in cutaneous lupus (CLE) will be presented at the AAD meeting; the program already has FDA Breakthrough Therapy designation, which could materially increase the drug’s commercial value if further data confirm benefit. Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data
• Positive Sentiment: Biogen launched a Phase 3 fumarate study targeting pediatric multiple sclerosis, expanding potential addressable market and signaling management’s push for growth outside its core older-adult neurology franchises. Biogen Targets Pediatric MS Growth With New Phase 3 Fumarate Study
• Positive Sentiment: BIIB080 Phase 1 imaging study completed — an early but necessary step in the Alzheimer’s program that reduces some development uncertainty and keeps the pipeline moving. Biogen’s BIIB080 Imaging Study Completes
• Positive Sentiment: An HSBC write‑up forecasting strong price appreciation for BIIB may bolster sentiment and buying interest from institutional investors. HSBC Forecasts Strong Price Appreciation for Biogen
• Neutral Sentiment: Biogen presented at the Stifel 2026 Virtual CNS Forum (investor transcript available) — useful for detail but unlikely to move the stock unless new guidance or surprises emerged. Biogen Presents at Stifel 2026 Virtual CNS Forum Transcript
• Neutral Sentiment: Short‑interest notices report a “significant increase” in March but show 0 shares / NaN change and a days‑to‑cover of 0.0 — the data look inconsistent, so treat any short‑pressure signal as uncertain until corrected.
• Negative Sentiment: The U.S. District Court for the District of Massachusetts certified a securities class action on behalf of Biogen purchasers, which introduces legal risk, potential costs and headline volatility. Securities Litigation Certified as Class Action

Insider Activity

In related news, insider Priya Singhal sold 2,660 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the sale, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.18% of the company’s stock.

Biogen Trading Up 0.6%

NASDAQ:BIIB opened at $183.49 on Friday. The stock has a market cap of $26.93 billion, a PE ratio of 20.83, a price-to-earnings-growth ratio of 1.45 and a beta of 0.15. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. The stock’s 50-day moving average is $184.18 and its two-hundred day moving average is $168.12.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping the consensus estimate of $1.61 by $0.38. The business had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm’s quarterly revenue was down 7.2% compared to the same quarter last year. During the same period last year, the company posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, equities research analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.